02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
21:36 , Jan 26, 2019 |  BioCentury  |  Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
22:33 , Nov 15, 2018 |  BC Innovations  |  Translation in Brief

The bystander effect of Treg depletion

Limiting bystander effects of immunosuppressive Treg-targeting therapies may be crucial for their antitumor efficacy, according to data released last week at the Society for Immunotherapy of Cancer meeting. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) presented...
17:00 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A biomanufacturing method could enable ex vivo production of human platelets to treat thrombocytopenia and other hematologic indications. In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks,...
15:46 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy CAR T cells engineered to express IL-7 and CCL19 could enhance the efficacy of T cell therapies for cancer. The method involves engineering solid tumor antigen-targeting CAR T cells, dubbed proliferation-inducing and...
04:20 , Dec 8, 2017 |  BC Week In Review  |  Financial News

OrbiMed , Thiel lead ChemomAb's $10M series B

Antibody company ChemomAb Ltd. (Tel Aviv, Israel) raised $10 million in a series B round on Dec. 4 led by OrbiMed Israel and Peter Thiel. SBI Japan-Israel Innovation Fund and Milestone Venture also participated. The...
23:06 , Dec 4, 2017 |  BC Extra  |  Financial News

OrbiMed, Thiel lead ChemomAb's $10M series B

Antibody company ChemomAb Ltd. (Tel Aviv, Israel) raised $10 million in a series B round led by OrbiMed Israel and Peter Thiel. SBI Japan-Israel Innovation Fund and Milestone Venture also participated. The company previously raised...
23:25 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Immune Pharmaceuticals reports additional Phase II data for bertilimumab in bullous pemphigoid

In September, Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) reported additional data from 6 patients with moderate to severe bullous pemphigoid in a Phase II trial showing that IV bertilimumab (CAT-213, iCo-008) led to a decline in...